CMK Global, a biomedical company in South Korea that specializes in manufacturing highly effective and well-researched medical devices, uses its cutting-edge technology to develop Kamomis dermal fillers. They consist of 3 types of fillers depending on their capability to enhance superficial to deep facial imperfections. These products are Kamomis Fine, Kamomis Deep, and Kamomis Volume. Each dermal filler contains unique benefits to improve and enhance the facial appearance. They have undergone multiple clinical trials and developed through meticulous research for over three years. Furthermore, they are formulated via an original 3D Crosslink Technology, wherein the filler bridges are entangled and unaligned hyaluronic acid in an even and stable structure. Unlike other products, Kamomis dermal fillers have high viscoelasticity by adding a second bridge to maintain a more stable form of hyaluronic acid gel. 

Kamomis dermal fillers use EP (European Pharmacopeia) standard hyaluronic acid, which is high in purity and of non-animal origin. Thus, Kamomis products are safe, as they have earned certifications and approval from regulatory authorities such as the US FDA and EDQM. With the innovative LCCP or Low Control Cross-linking Technology, Kamomis products guarantee their durability and exceptional viscosity. This is done by efficiently combining hyaluronic acid and BDDE with the appropriate ratios to attain the best formula, achieving a stable 3D structure. CMK Global ensures that Kamomis dermal fillers push boundaries with their formula’s high elasticity, cohesion, and uncompromised purity. Kamomis dermal fillers produce quick and immediate effects, making patients highly satisfied.